GLP-1 Insurance Coverage in 2026: A Complete Guide

The coverage landscape has shifted dramatically over the past three years. In 2022, fewer than 20 percent of commercial insurance plans covered Wegovy or other GLP-1s for obesity. By the end of 2025, that number had risen to approximately 50 to 60 percent for medium and large employers, driven by competitive pressure as employees demanded coverage and as cost-effectiveness data accumulated.

The coverage story breaks down by plan type:

Large employer self-funded plans: Approximately 60 to 70 percent now cover GLP-1s for obesity with BMI criteria. Many require step therapy (you must have tried lifestyle intervention or older weight loss medications first).

Small employer fully-insured plans: Closer to 40 to 50 percent coverage. Rising premiums are a barrier — small employers feel the GLP-1 cost more acutely.

ACA Marketplace plans: Highly variable by state and carrier. Some states (like New York) mandate coverage; others leave it to plan discretion.

Medicaid: Approximately 25 states cover GLP-1s for obesity in some form as of early 2026, often with strict prior authorization and BMI cutoffs.

Medicare Part D: Statutorily excludes weight loss medications. The Inflation Reduction Act and the Treat and Reduce Obesity Act would change this, but as of May 2026, no statutory change has been enacted. Medicare does cover GLP-1s for type 2 diabetes, cardiovascular risk reduction (Wegovy specifically), and obstructive sleep apnea (Zepbound was approved for OSA in December 2024).

Prior authorization (PA) is the single biggest hurdle most patients face. About 80 percent of commercial plans require PA for GLP-1s, and the denial rate on first submission is high — often 30 to 40 percent.

Common PA requirements:

• •Documented BMI ≥30 (or ≥27 with a comorbidity such as hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or established cardiovascular disease)
• •3 to 6 months of documented attempts at lifestyle modification (diet and exercise)
• •For some plans, a trial of older anti-obesity medications (phentermine, orlistat, naltrexone/bupropion)
• •A formal weight loss program enrollment in some cases
• •Clinical notes documenting medical necessity

What gets PAs approved: Detailed clinical notes from your provider that explicitly state BMI, comorbidities, prior weight loss attempts with dates and results, and a clear treatment plan with a follow-up schedule. Vague notes like 'patient wants Wegovy for weight loss' almost always get denied. Specific notes like 'BMI 33, comorbid hypertension and prediabetes, has completed 6 months of WW with 4 lb loss, requesting initiation of semaglutide per Wegovy package insert' frequently succeed.

If denied: Almost all denials can be appealed. The first-level appeal is often a peer-to-peer review where your prescriber speaks directly with the insurance company's medical director. Approval rates on appeal range from 50 to 70 percent, depending on plan and documentation. Do not give up after one denial.

Manufacturer savings cards (also called copay cards or copay assistance) are the single highest-leverage cost tool for commercially insured patients. They are typically NOT available to patients on government insurance (Medicare, Medicaid, VA, Tricare).

Wegovy Savings Offer (Novo Nordisk): Eligible commercially insured patients with coverage pay as little as $0 per month for up to 13 fills (about a year). If your plan does NOT cover Wegovy, the savings card may reduce the cost by approximately $500 per month off list price.

Zepbound Savings Card (Eli Lilly): Eligible commercially insured patients with coverage pay as little as $25 per month for up to 13 fills. For patients without coverage, the savings card can reduce list price by approximately $469 per month.

Ozempic Savings Offer (Novo Nordisk): Limited to patients with type 2 diabetes. Eligible patients with commercial coverage pay as little as $25 per month.

Mounjaro Savings Card (Eli Lilly): Limited to patients with type 2 diabetes. Eligible commercially insured patients pay as little as $25 per month.

Rybelsus Savings Offer (Novo Nordisk): Eligible commercially insured patients with type 2 diabetes pay as little as $10 per month.

These cards have annual caps, eligibility windows, and renewal requirements. Always download or activate the current version from the manufacturer's website before your first fill — pharmacists do not automatically apply them.

In August 2024, Eli Lilly launched LillyDirect, a direct-to-consumer program offering Zepbound in single-dose vials at significantly reduced prices for self-pay patients. This was a strategic response to the compounding market — Lilly's pitch is brand-name medication at a price closer to compounded.

LillyDirect Zepbound Vial Pricing (as of 2026): - 2.5 mg starter dose: $349/month - 5 mg dose: $499/month - 7.5 mg and 10 mg doses: pricing announced for ongoing rollout

How it works: Patients sign up at LillyDirect.com, complete a telehealth evaluation through a third-party provider, and receive a 4-week supply mailed to their home. Self-pay only — not billable to insurance, including Medicare or Medicaid.

Caveats: The vials require self-drawn injection (using a syringe to extract the dose from a vial), unlike the pre-filled pens. Some patients find this intimidating; others appreciate the lower cost. The highest doses (12.5 mg and 15 mg) are not yet available as vials.

For self-pay patients, this is generally cheaper than compounded tirzepatide in 2026, with the obvious advantage of being a brand-name product. For more context on the broader brand-vs-compounded landscape, see our [compounded semaglutide guide](/blog/compounded-semaglutide-vs-brand-cost-safety-2026).

Yes, and most patients underuse this option. Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) allow you to pay for GLP-1 medications with pre-tax dollars when they are prescribed for a covered medical condition — which includes obesity and type 2 diabetes.

HSA: Pre-tax dollars, rolls over year to year, requires a high-deductible health plan. You can use HSA funds for the copay portion or for self-pay amounts. Saves you the marginal tax rate — typically 22 to 32 percent for many middle-income earners.

FSA: Pre-tax dollars, use-it-or-lose-it within the plan year (with limited carryover). Same eligibility as HSA for GLP-1 expenses.

Documentation: Some HSA/FSA administrators require a Letter of Medical Necessity from your provider for weight loss medications, even if the medication is FDA-approved for obesity. Ask for one if requested.

Practical math: A patient self-paying $500/month for Zepbound vials, in the 24 percent tax bracket, saves about $1,440 per year by using HSA dollars. Worth setting up if you do not already have one.

Note that some plans (especially limited-purpose FSAs) exclude weight loss medications. Check your plan documents.

This is one of the cruelest twists in GLP-1 insurance. Many plans require you to maintain a BMI threshold to continue receiving the medication. Once your BMI drops below 27 (or below 30 without a comorbidity), some plans will discontinue coverage — at exactly the point when you would benefit from continued maintenance dosing.

The maintenance dilemma: Obesity medicine specialists overwhelmingly recommend continuing GLP-1 medications long-term, often at lower maintenance doses, because the SURMOUNT-4 trial showed that stopping tirzepatide led to regain of approximately 14 percent of body weight within a year, undoing two-thirds of the weight loss. The medication treats a chronic condition, not a one-time problem.

Working around this: If your plan threatens to discontinue coverage after you reach a healthy BMI:

1. Discuss with your provider whether a lower maintenance dose is appropriate (often 2.5 mg or 5 mg tirzepatide, or 0.5–1 mg semaglutide) 2. Document the regain risk in your clinical notes 3. Some plans will continue coverage for maintenance with documentation of clinical necessity 4. If denied for maintenance, the LillyDirect vial program or savings cards become especially valuable

For more on what happens at the weight loss plateau, see our [Wegovy plateau guide](/blog/weight-loss-plateau-on-wegovy-what-to-do-when-the-scale-stops).

Medicare's exclusion of weight loss medications has been one of the most contested policy issues in obesity medicine. As of May 2026, the statutory exclusion remains, but several workarounds exist.

Medicare Part D coverage of GLP-1s for non-obesity indications:

• •Ozempic, Mounjaro, Rybelsus: Covered for type 2 diabetes. If you have a T2D diagnosis, you can access GLP-1s via Medicare Part D.
• •Wegovy: In March 2024, CMS clarified that Wegovy is covered for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity following the SELECT trial. This is a substantial pathway — see our [GLP-1 and heart health guide](/blog/glp-1s-and-heart-health-what-the-select-trial-changed) on the SELECT trial findings.
• •Zepbound: In December 2024, FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Medicare Part D coverage for OSA followed in early 2025.

For Medicare patients without diabetes, CV disease, or OSA, the options narrow significantly: out-of-pocket purchase via the LillyDirect vial program, or affordable self-pay options for compounded medications (though FDA compounding restrictions have tightened in 2025–2026).

The Treat and Reduce Obesity Act, if eventually passed, would explicitly authorize Medicare coverage for obesity medications. Advocacy organizations including the Obesity Action Coalition continue to push for this change.

Five steps to find your actual coverage in under 30 minutes:

1. Pull your formulary. Log into your insurance member portal and search for the specific brand name (Wegovy, Zepbound, Mounjaro, Ozempic, Rybelsus). The formulary lists tier and any restrictions.

2. Check tier and restrictions. Tier 3 or 4 means covered with a higher copay. 'PA' means prior authorization required. 'ST' means step therapy. 'QL' means quantity limit. 'NF' means not on formulary.

3. Call member services. Ask: 'Is [medication name] covered for the obesity indication?' Some plans cover for diabetes only — the question matters.

4. Get the PA criteria in writing. Most plans will email or fax their PA criteria so you can review with your provider before submission.

5. Check your deductible status. Even covered medications cost full price until you hit your deductible. A $1,000 deductible on Wegovy is roughly your first month's worth out-of-pocket before copays kick in.

If you are uninsured or your plan does not cover, start with the manufacturer savings card website. Both Novo Nordisk and Eli Lilly have eligibility checkers that estimate your out-of-pocket within 60 seconds.

Yes, though they are stricter than savings cards.

Novo Nordisk Patient Assistance Program (PAP): Provides free Wegovy or Ozempic for eligible uninsured patients meeting income criteria — typically up to 400 percent of the federal poverty level. Application requires income documentation and prescriber attestation. Process takes 2 to 4 weeks; approvals are good for one year.

Lilly Cares (Eli Lilly): Similar program for Mounjaro and Zepbound. Income eligibility typically up to 400 percent FPL.

Independent foundations: Patient Advocate Foundation, NeedyMeds, and HealthWell Foundation offer copay grants when funds are available — but obesity-specific funds are limited and often close to new applicants quickly.

For patients between Medicaid eligibility and a full commercial salary — the classic insurance coverage gap — these programs are sometimes the only path to access.

Two big shifts are likely to reshape coverage over the next 2 years:

Cardiovascular and metabolic indications expand. The SELECT trial's cardiovascular endpoints opened Medicare coverage for Wegovy in CV disease. The FLOW trial showed kidney protection. Additional trials (SURMOUNT-MMO, SUMMIT) are likely to expand coverage further — every new indication shifts coverage decisions in favor of patients.

Price competition intensifies. With orforglipron, retatrutide, and other next-generation molecules launching in 2026 to 2028, expect downward pressure on prices. Eli Lilly and Novo Nordisk's direct-to-consumer programs may expand to additional doses and additional medications.

Employer coverage stabilizes. After years of dramatic year-over-year shifts, large employer coverage of GLP-1s for obesity is settling around 60 to 70 percent. Coverage criteria continue to tighten (more required PA criteria, more step therapy) but outright drops in coverage have stabilized.

The practical takeaway: 2026 is the best coverage environment patients have ever had, and it's getting better, not worse. If you were denied two years ago, it is worth reapplying now.